COMBINATION OF PEGYLATED LIPOSOMAL DOXIL WITH PS-341 IN PATIENTS WITH MALIGNANC

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究研究的目的是：1)找出一种名为PS-341的研究药物与另一种名为Doxil的药物联合使用的最高安全剂量；2)确定这两种药物联合使用的副作用；3)研究这两种药物联合使用的人体方式；4)研究接受这种治疗的受试者的生活质量；5)寻找肿瘤反应的迹象。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purposes of this research of this research study are: 1) to find out the highest dose that is safe to use of an investigational drug called PS-341 given in combination with another drug called Doxil; 2) to determine the side effects of this combination; 3) to study the way the body clears these two drugs in combination; 4) to study the quality of life of subjects receiving this treatment and 5) to look for signs of tumor response.